1. Introduction {#sec1-diagnostics-07-00039}
===============

Laboratory testing remains the dominant mainstay for analytical processes of a large number of samples involving the disciplines of biochemistry, haematology, microbiology, anatomical pathology, and much more \[[@B1-diagnostics-07-00039]\]. Due to the limitations and pressure on healthcare budgets faced by a very large number of countries, primary care is best suited for the world to reduce expenses instead of secondary and tertiary hospitals. Poverty, chronic disease, infections lead to significant problems in developing the world, and adequate diagnostic testing turns out to be difficult to meet the needs. Hence, consequently, initiatives in making solid models using point-of-care technology (PoCT) came into existence \[[@B2-diagnostics-07-00039]\].

1.1. Paradigm Shift from Central Laboratory (CL) to Point-of-Care {#sec1dot1-diagnostics-07-00039}
-----------------------------------------------------------------

A self-monitoring blood glucose meter, coagulation (INR), and pregnancy testing kits using urine samples are well-known examples of PoCT and has become over-the-counter products to be sold in the market. Saliva is predicted to be a substitute for blood, collected non-invasively for the diagnosis of oral and systemic diseases. Thus, PoCT replaces the specialist testing centres by using the samples other than blood and urine \[[@B3-diagnostics-07-00039]\]. For the development of PoCT devices, minimum risk of infection with no mental and physical pain is of utmost importance to consider, in addition to automation, integration, multiplexed detection ability, quick analysis, small sample size, and minimal training as the primary goals of modern medicine \[[@B4-diagnostics-07-00039]\]. With the advent of the struggle in the growing potential of developing PoCT, the World Health Organization (WHO) provided guidelines which had the features for designing devices, known as the ASSURED criteria, which indicated that devices had to be affordable, sensitive, specific, user-friendly, rapid and robust, with no complex equipment, and be delivered to end users efficiently.

The precision to central lab testing is being facilitated by the use of biomarkers and saliva is a viable biofluid for diagnostic applications. The human saliva revolution in medical and dental sciences through its property as a "*mirror of body health*" in the last decade brought many disease detections through its compositional changes in disease conditions \[[@B5-diagnostics-07-00039]\]. Human oral cavity consists of different sources, such as salivary glands (major and minor), gingival crevicular fluid (GCF), microbes, and oral epithelial sheds for the production of whole mouth fluid (WMF) \[[@B6-diagnostics-07-00039],[@B7-diagnostics-07-00039],[@B8-diagnostics-07-00039],[@B9-diagnostics-07-00039],[@B10-diagnostics-07-00039],[@B11-diagnostics-07-00039],[@B12-diagnostics-07-00039]\]. This fluid is 99% water, but 1% consists of DNA, mRNA, microRNA, proteins, metabolites, and microbiota which are utilised as a diagnostic fluid for disease analysis and even for forensic analysis \[[@B13-diagnostics-07-00039],[@B14-diagnostics-07-00039]\]. In this particular review, we present the current knowledge of saliva, diagnostic toolboxes, how PoC technology works, developed PoC devices for detection of various diseases, and the future prospects of utilising saliva as a diagnostic tool.

1.2. Saliva in the Diagnosis of Oral and Systemic Diseases {#sec1dot2-diagnostics-07-00039}
----------------------------------------------------------

Saliva is a complex fluid containing various enzymes, electrolytes, proteins, nucleic acids, antimicrobial constituents, hormones, cytokines, and antibodies. Its composition virtually reflects the entire state of health and disease in a body and it has the potential of being a diagnostic medium for a broad range of diseases \[[@B15-diagnostics-07-00039],[@B16-diagnostics-07-00039]\], such as in the detection of periodontal diseases, caries risk assessments, breast cancer, oral cancers, salivary gland diseases, HIV, and much more \[[@B16-diagnostics-07-00039]\]. However, the effects of alteration in the salivary composition are seen in the lipid profile of cystic fibrosis patients, which is markedly changed in comparison to healthy subjects \[[@B17-diagnostics-07-00039]\]. The submandibular gland saliva of cystic fibrosis patients contains 66% more lipids per 100 mL of saliva than that of a healthy subject. The salivary fatty acid profile can be a good indicator for the early detection of tumorigenesis processes and cardiovascular diseases. The increase in production of salivary arachidonic acid, relevant for their eicosanoid production related to the tumorigenesis process and cardiovascular diseases, is influenced by dietary fat intake \[[@B18-diagnostics-07-00039]\]. [Figure 1](#diagnostics-07-00039-f001){ref-type="fig"} portrays alterations of biomarkers in various body organs in diseased states through which saliva can detect a variety of oral and systemic diseases.

Similarly, in Sjogren's syndrome (SS) the saliva flow is compromised in the patient due to ductal changes by lymphocytic infiltration and fibrosis of the salivary glands and the patient also suffers from the consequences of dental caries, infections dysphagia, and other oral pain \[[@B19-diagnostics-07-00039]\]. The lipid profile of SS patients is twice higher than an average healthy person and elevated level of cytokines (IgA, IgG, interleukin-6, and prostaglandins-E2) and antibodies. Many salivary proteins were reported as biomarkers for SS diagnosis; for example, profilin \[[@B20-diagnostics-07-00039]\], anhydrase-I \[[@B21-diagnostics-07-00039]\], IL-4, IL-5 \[[@B22-diagnostics-07-00039]\], MxA \[[@B23-diagnostics-07-00039]\], and CXCL13 \[[@B24-diagnostics-07-00039],[@B25-diagnostics-07-00039]\]. Human saliva has a proven diagnostic role in the detection of cardiovascular diseases, reported in studies examining whole mouth salivary biomarkers e.g., C-reactive proteins (CRP) \[[@B26-diagnostics-07-00039]\], cardiac troponin (cTn) \[[@B27-diagnostics-07-00039]\], creatine phosphokinase \[[@B28-diagnostics-07-00039]\], and NT-ProBNP \[[@B29-diagnostics-07-00039]\]. Diabetes is another common disease faced all around the world and developing rapidly due to dietary habits, genetic, and other systematic disease-related complications \[[@B30-diagnostics-07-00039]\]. Due to its non-invasiveness, a cheap and easy sampling of saliva is attractive as a diagnostic fluid for diabetes analysis \[[@B31-diagnostics-07-00039]\]. Previously reported studies concluded the different biomarkers for diabetes detection in early stages. A recently-reported study saw a marked alteration in levels of salivary glucose, amylase, calcium, and phosphorus in comparison to serum from diabetic and non-diabetic patients \[[@B32-diagnostics-07-00039]\], as seen in [Table 1](#diagnostics-07-00039-t001){ref-type="table"} below.

The current review presents a broad overview on salivary diagnostics, the validation of biomarkers (diagnostic targets) through diagnostic toolboxes, discussion related to new biomarker-related PoC platforms, the latest emerging PoC technologies including highlights on biosensors, biological micro-electro-mechanical systems (BioMEMS), microfluidics/paper based technology, electric field-induced release and measurement (EFIRM), and smartphone-based biosensors their functions and clinical utility in medical field.

2. Point-of-Care Technology: An Overview {#sec2-diagnostics-07-00039}
========================================

Point-of-care (PoC) technology in diagnostics tends to evaluate biomarkers that are suggestive of underlying biological or physical characteristics of an individual. Therefore, biomarkers determine the risk and severity of the disease, as well as the individual's response to treatment \[[@B15-diagnostics-07-00039]\]. In addition to it, diagnostic methodologies other than biomarkers also include biochip and biosensor systems. Biochip systems obtain the requisite volume of saliva for testing whereas the biosensor system is the analytical high-sensitive technology for the detection of biomarkers \[[@B50-diagnostics-07-00039]\]. Accurate PoC diagnostics needs no pre-processing and screening for biomarker identification on top of it non-invasive testing, as seen in already-patented devices, such as for the detection of oral cancer known as the Oral Fluid NanoSensor Test (OFNASET), the detection of human papillomavirus (HPV) infection OraRisk HPV test, and the diagnosis of periodontal diseases PerioPath \[[@B51-diagnostics-07-00039],[@B52-diagnostics-07-00039]\]. Moreover, measuring the molecular level biomarkers in the form of proteins, mRNA, DNA, electrolytes, and small molecules requires techniques of microfabrication, such as in the developed micro/nanoelectromechanical systems (MEMS/NEMS) \[[@B53-diagnostics-07-00039]\], and current emerging technologies provide new avenues of PoC diagnostics in the variety of "lab-on-chip" techniques which integrates the complexities of lab procedures on a computer chip in the size of a device that, hence, gives an opportunity to detect and diagnose multiple diseases simultaneously with the help of biomarkers \[[@B54-diagnostics-07-00039]\].

2.1. Diagnostic Targets {#sec2dot1-diagnostics-07-00039}
-----------------------

Salivary diagnostics needs appropriate identification and validation of biomarkers for the detection of diseases, and a biomarker is a quantifiable parameter that can interact physiologically and biochemically at a molecular or cellular level, which sequentially acts as an indicator of normal, pathological, and interventional behaviours of the body's response \[[@B55-diagnostics-07-00039],[@B56-diagnostics-07-00039]\]. Biomarkers include several classes, such as proteins, DNA, RNA, metabolites, and microbes, so collectively these all are used for diagnosis of several diseases and are called a molecular signature \[[@B57-diagnostics-07-00039]\].

2.2. Diagnostic Toolboxes {#sec2dot2-diagnostics-07-00039}
-------------------------

Major salivary diagnostic tool boxes include proteomes, metabolomes, genomes (transcriptome, epigenome), microbiomes, and immunologic categories. [Table 2](#diagnostics-07-00039-t002){ref-type="table"} shows the variety of methods used to analyse molecules for the investigation and validation of biomarkers. Proteomes make up the biological system and could be employed for the detection of diabetes, periodontitis, caries, cystic fibrosis, AIDS, OSCC, breast cancer, lung cancer, pancreatic cancer, Sjogren's syndrome, and many more through mass spectroscopy, 2D gel electrophoresis, ELISA and protein immunoblot techniques \[[@B58-diagnostics-07-00039],[@B59-diagnostics-07-00039],[@B60-diagnostics-07-00039],[@B61-diagnostics-07-00039]\]. However, mRNA and DNA come under salivary transcriptomes and genomes, and their profiling through gene chip arrays, DNA hybridization, qPCR, and gel electrophoresis helps in the detection of OSCC, as conducted by Li et al. \[[@B62-diagnostics-07-00039]\], and in Sjogren's syndrome, hepatitis, HIV, etc. The metabolic investigation, on the other hand, requires and uses gas chromatography mass spectrometry, nuclear magnetic resonance spectroscopy, and high-performance liquid chromatography \[[@B63-diagnostics-07-00039]\] for the detection of diabetes, lung, pancreatic, breast cancers, and Sjogren's syndrome \[[@B64-diagnostics-07-00039],[@B65-diagnostics-07-00039]\]. In the same way, the salivary microbiome and immnomics used different methods, as mentioned in the table for the detection of infectious diseases, HIV, hepatitis, malaria, dengue, Ebola virus, cytomegalovirus, herpes infection, and countless other diseases \[[@B66-diagnostics-07-00039],[@B67-diagnostics-07-00039],[@B68-diagnostics-07-00039]\].

2.3. Salivary Biomarker-Based PoC Platforms {#sec2dot3-diagnostics-07-00039}
-------------------------------------------

In [Table 3](#diagnostics-07-00039-t003){ref-type="table"}, shows analysis system based on different technologies applied on saliva for the detection of biomarkers to reduce the time duration and early diagnosis of certain diseases. As shown in table it is revealed that single and multiplexed systems were being used such as MEMS, ORI, chromatography test strips and several salivary diagnostics devices (USA) for the detection of proteins solely, also proteins and nucleic acids altogether (for e.g., IL-8, MMP-8, a-amylase, HIV, HCV) with lowering the time limit as much little as one minute. These technologies, therefore, reduces the invasive procedures significantly to a larger level \[[@B16-diagnostics-07-00039]\].

3. Emerging Novel PoC Technologies {#sec3-diagnostics-07-00039}
==================================

3.1. Biosensors {#sec3dot1-diagnostics-07-00039}
---------------

The biosensor is a bioanalytical device which has the ability to mimic any biological material, i.e., antibodies/antigens, nucleic acids, cellular structures or enzymes. That organic material is integrated into a transducing microsystem. The transducer could be electrochemical, thermometric, optical, piezoelectric, or magnetic, and this is called label-free detection \[[@B74-diagnostics-07-00039]\], while label-based detection includes fluorescent immunoassays, FRET, and quantum dots. Biosensors function with the biorecognition of particular elements for particular targeted analytes and the maintenance of selectivity and sensitivity in the existence of other interfering compounds \[[@B75-diagnostics-07-00039]\]. In the medical field, biosensor applications are growing rapidly, such as for the diagnosis of diabetes mellitus, urinary tract infections (UTI), identification of end-stage heart failure, and acute leukaemias ([Table 1](#diagnostics-07-00039-t001){ref-type="table"}) \[[@B76-diagnostics-07-00039]\].

3.2. Fluorescent Biosensors {#sec3dot2-diagnostics-07-00039}
---------------------------

Fluorescent biosensors can be used for cancer, drug discovery, arthritis, cardiovascular and neurodegenerative diseases, viral infections, chronic myeloid leukemia, and many more, by using the principal of high throughput screening approaches, the use of fluorescent probes in gene expression, localization of protein in cell cycle, apoptosis, signal transduction, and transcription. For the detection of chronic myeloid leukaemia, a genetically-encoded FRET biosensor was developed to detect Bcr-Abl kinase activity to see the correlation, it was further used to check the response to treatment, drug resistance, and predictive values for alternative therapeutics \[[@B77-diagnostics-07-00039]\]. Moreover, Lee et al. applied hafnium oxide in a novel biosensor for the detection of human interleukin (IL-10) (atomic layer deposited hafnium oxide gate dielectrics for charge-based biosensors) \[[@B78-diagnostics-07-00039]\]. Applications of nanomaterial biosensors give opportunities for a new generation of biosensor technologies that can be broadly used in monitoring, diagnosis, control, and analysis.

3.3. Biological Micro-Electro-Mechanical Systems (BioMEMS) {#sec3dot3-diagnostics-07-00039}
----------------------------------------------------------

PoC lab-on-chip systems use small and simply-constructed (BioMEMS) devices for the detection of biological and chemical agents. BioMEMS are utilized for the detection of cells, proteins, microorganisms, viruses, and DNA in biological samples. They are based on micro/nanoscale fabrication systems which help in increasing the sensitivity of results from sensors, increased reliability, increased performance, reduced detection time, and cost effectiveness. It has label-free detection techniques, including micro-cantilevers, surface plasmon resonance (SPR), quartz crystal microbalances (QCM), and organic field-effect transistors (BioFETs) \[[@B79-diagnostics-07-00039]\]. BioMEMS are used for a range of applications, such as for drug delivery, cardio MEMS to monitor heart patients, hearing aids, insulin micropumps, endoscopic pills, and retinal prosthesis \[[@B80-diagnostics-07-00039],[@B81-diagnostics-07-00039]\] ([Table 3](#diagnostics-07-00039-t003){ref-type="table"}). By blending molecular biology with computational systems, the major nanotechnology achievement could be bio-nano-electro-mechanical systems (BioNEMS) in the future for further improvements in the medical sector.

3.4. Microfluidics/Paper-Based Technology {#sec3dot4-diagnostics-07-00039}
-----------------------------------------

Microfluidic applications operate on integrated microfabrication and specific physiochemical properties. Initially, the use of silicon, inorganic glass, and ceramic was used in microfluidic devices which have been vastly replaced by the soft and rigid thermostatic and thermoplastic materials and, finally, into paper-based technologies, using biodegradable and hydrogel materials \[[@B82-diagnostics-07-00039]\]. At Harvard University in 2007 microfluidic paper-based analytical devices (μPADs) were pioneered by Whitesides. Paper is porous and hydrophilic, therefore, it provides a platform for the fabrication of microfluidic channels by patterning the paper with 2D and 3D μPADs and having a variety of assay designs. They are used in the detection of urine metabolites, blood glucose, pH value, liver function, and infectious agents, and they are also widely used in pregnancy test kits \[[@B83-diagnostics-07-00039]\].

3.5. Electric Field-Induced Release and Measurement (EFIRM) {#sec3dot5-diagnostics-07-00039}
-----------------------------------------------------------

A liquid biopsy technique called EFIRM, uses readout enzymes and immobilised probes for the capturing and detection of biomarkers from biofluids. EFIRM uses the electrochemical method to facilitate nucleic acid hybridization. This approach is advantageous for accurate detection of RNA, protein biomarker targets in exosomes. Additionally, without the extraction of DNA and nucleic acid, EFIRM can analyse the mutation status within an hour. IL-8 protein and IL-8 mRNA markers for oral cancer, non-squamous cell lung cancer (NSCLC) oncogenic mutation, and epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer can be detected through this EFIRM system \[[@B57-diagnostics-07-00039],[@B84-diagnostics-07-00039]\].

3.6. Smartphone-Based Biosensors {#sec3dot6-diagnostics-07-00039}
--------------------------------

Smartphones operate similarly to miniature computers, acting as cheap, portable analytical laboratory devices. They are helpful for the detection, and diagnosis, of various diseases, such as cancer, tuberculosis, and the self-monitoring of blood glucose. [Figure 2](#diagnostics-07-00039-f002){ref-type="fig"} illustrates the few shapes and designs of currently-used PoC technologies while [Table 4](#diagnostics-07-00039-t004){ref-type="table"} shows all the functions, techniques, and clinical utilities of these techniques in a concise manner.

Recent advancements in smartphones electronics and new app development have made its use as a smart detector by having all the mixed optical methods, i.e., fluorescence, surface plasmon resonance (SPR), reflectance, absorbance, bio-chemiluminescence, and electrochemiluminescence \[[@B85-diagnostics-07-00039]\]. Amongst them all SPR gained importance because of its high sensitivity, label-free, microfluidic technique. Conventional SPR utilizes planar thin gold film while localized SPR (LSPR) contains metal nanostructures \[[@B86-diagnostics-07-00039]\]. Hence, SPR becomes the powerful tool in biomedical application such as for the study of several DNA, RNA, proteins, lipids, carbohydrates, even mutation detection \[[@B87-diagnostics-07-00039]\]. Moreover, Lee et al. described the smartphone's function as a compact microscope in which ambient illumination as a light source was being used instead of a chip-scale method. This lensless imaging scheme allows sub-micron resolution and the built-in android application brings simplicity, robustness, and employability for several field applications \[[@B88-diagnostics-07-00039]\].

4. Future Direction and Conclusions {#sec4-diagnostics-07-00039}
===================================

This article gives an overview of research in molecular diagnostics, microbiology, and immunology. Routine laboratory testing includes the majority of haematology testing, clinical chemistry, and immunochemistry by using high-throughput instrumentation. Therefore, salivary PoCT diagnostics is replacing the central laboratory and offers efficient, fast, quick and easy automation. Since the emphasis is switching more towards prevention and early detection of a variety of diseases, development of small wireless devices has made a dramatic impact on healthcare services. The next decade will bring breakthroughs in terms of precision, efficiency, and bedside monitoring instead of hospital setups.

Personalised medicine, with the help of biosensors, lab-on-chip systems, individual genetics, smartphones monitoring parameters, and microfluidic devices, will improve the primary healthcare system. Moreover, it allows clinicians to be accurate, to be more consistent, to capture clinical data quickly, provide patient satisfaction, and streamline workflow. Salivary diagnostics' impact on the healthcare system is enormous, being non-invasive, convenient, and well-credentialed, while bioinformatics introduction will make standards and performance higher and improved.
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diagnostics-07-00039-t001_Table 1

###### 

Description of Point-of-care (PoC) devices for detection of diseases through specific salivary biomarkers.

  Salivary Biomarkers                                                                            Diseases/Conditions                                                                                Developed PoC                                                                        References
  ---------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------ -------------------------------------------------------------
  A-amylase                                                                                      Clinical judgment for stress-induced disease                                                       Salivary α-Amylase (sAA) biosensor system                                            \[[@B33-diagnostics-07-00039]\]
  HIV                                                                                            AIDS                                                                                               Oraquick, tablet-based kiosks                                                        \[[@B34-diagnostics-07-00039],[@B35-diagnostics-07-00039]\]
  Hep C                                                                                          Hepatitis                                                                                          OraQuick                                                                             \[[@B36-diagnostics-07-00039]\]
  HPV                                                                                            HPV-associated cancers, sexually transmitted diseases                                              simple fluorescent and colorimetric assay that enables DNA and RNA detection         \[[@B37-diagnostics-07-00039]\]
  Cortisol                                                                                       Stress levels                                                                                      Label-free chemiresistor immuno-sensor                                               \[[@B38-diagnostics-07-00039]\]
  Proteins (Dipeptidyl peptidase etc.), metabolites, DNA                                         Periodontitis                                                                                      Integrated Microfluidic Platform for Oral Diagnostics (IMPOD), lab-on-a-chip (LOC)   \[[@B39-diagnostics-07-00039]\]
  C-reactive protein, myoglobin, and myeloperoxidase                                             Acute Myocardial Infarction                                                                        Luminex, lab-on-a-chip methods                                                       \[[@B40-diagnostics-07-00039]\]
  Cytokines                                                                                      Asthma and chronic obstructive pulmonary disease (COPD)                                            Fiber-optic microsphere-based antibody array                                         \[[@B41-diagnostics-07-00039]\]
  IL-8, IL-8mRNA                                                                                 Oral Cancer                                                                                        Electrochemical magneto biosensors                                                   \[[@B42-diagnostics-07-00039]\]
  (NO~2~− and uric acid), and pulmonary inflammation biomarkers                                  End-stage renal disease (ESRD), asthma and chronic obstructive pulmonary disease (COPD) patients   Optical fibre microarrays                                                            \[[@B43-diagnostics-07-00039]\]
  Salivary nicotine metabolites                                                                  Smoking/tobacco use                                                                                Point of care test for salivary nicotine metabolites                                 \[[@B44-diagnostics-07-00039]\]
  *Porphyromonas gingivalis*                                                                     chronic periodontitis                                                                              *P. gingivalis* saliva kit                                                           
  Gonorrhoea and chlamydia                                                                       Sexually transmitted infections (STIs)                                                             Oral STI point-of-care (PoC)                                                         \[[@B36-diagnostics-07-00039]\]
  Salivary anti-Ro60 and anti-Ro52 Antibody Profiles                                             Sjögren's Syndrome                                                                                 Luciferase Immunoprecipitation Systems (LIPS)                                        \[[@B45-diagnostics-07-00039]\]
  Salivary glucose                                                                               Diabetes                                                                                           Glucose monitoring using saliva nanostructured biosensor                             \[[@B46-diagnostics-07-00039],[@B47-diagnostics-07-00039]\]
  cRP, MPo, ctnl, Myo, cK-MB, d-dimer, apoa1, apoB, BnP, nt-proBnP, scd40l, McP-1, adiponectin   Cardiovascular disease (CVD)                                                                       Programmable bio-nanochip (P-BNC) system                                             \[[@B48-diagnostics-07-00039]\]
  cea, ca125, Her2-neu, Psa (free and complexed)                                                 Cancer                                                                                             Programmable bio-nanochip (P-BNC) system, 2D nanomaterials                           \[[@B48-diagnostics-07-00039],[@B49-diagnostics-07-00039]\]

diagnostics-07-00039-t002_Table 2

###### 

Methods used for the evaluation of diagnostic toolboxes.

  Diagnostic Toolbox                           Methods of Evaluation                                                                                                                                                                                                                                                                                             Molecules to Be Analysed                                                                                                                                                    References
  -------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------
  Proteomics                                   Mass spectroscopy and 2D gel electrophoresis, ELISA, protein immunoblot techniques                                                                                                                                                                                                                                Post-translational modifications and protein-enzyme complexes                                                                                                               \[[@B69-diagnostics-07-00039]\]
  Genomics (Transcriptomics and Epigenomics)   Gene chip arrays, DNA hybridization, qPCR, and gel electrophoresis                                                                                                                                                                                                                                                DNA, RNA and mRNA                                                                                                                                                           \[[@B70-diagnostics-07-00039]\]
  Metabolomics                                 Nuclear magnetic resonance spectroscopy (NMR), gas chromatography-mass spectrometry, direct flow injection/liquid chromatography-mass spectrometry, inductively coupled plasma mass spectrometry, and high-performance liquid chromatography (HPLC), capillary electrophoresis time of flight mass spectroscopy   Small molecules end products of metabolic processes in the body such as organic species, together with non-protein hormones (epinephrine, peptide hormones and cortisol).   \[[@B71-diagnostics-07-00039]\]
  Microbiome                                   Bacterial microarrays, DNA hybridization, PCR, next-generation sequencing, and quantitative 16S rRNA gene sequencing, oligonucleotide microarray based on 16S rRNA, aptly named human-microbe identification microarrays (HOMIM)                                                                                  Bacterial species (*Streptococcus*, *Staphylococcus*)                                                                                                                       \[[@B68-diagnostics-07-00039],[@B72-diagnostics-07-00039],[@B73-diagnostics-07-00039]\]
  Immunomics                                   Immunologic analysis                                                                                                                                                                                                                                                                                              Immunological markers (IgM, IgA, and IgG tests, and hepatitis B virus and hepatitis C virus, IgG)                                                                           \[[@B67-diagnostics-07-00039]\]

diagnostics-07-00039-t003_Table 3

###### 

Examples of single and multiplexed salivary biomarker-based PoC diagnostics \[[@B9-diagnostics-07-00039]\].

  PoC Platforms                System Used                                                                                        Biomarker                             Test Duration                Region of Origin
  ---------------------------- -------------------------------------------------------------------------------------------------- ------------------------------------- ---------------------------- ---------------------------
  Single                       Microelectromechanical technology (MEMS), optical fluorescent system followed by electrophoresis   Matrix metalloproteinase-8 MMP        10 min                       Sandia National Lab (USA)
  Oral risk indicator ORI      MMP-8                                                                                              Less than 10 min                      Dentognostics (Germany)      
  Chromatography test strips   HIV1&2, HCV, influenza                                                                             20 min                                Orasure Technologies (USA)   
  Handheld device              Cortisol, a-amylase                                                                                1 min                                 Nipro (Japan)                
  Multiplexed                  Salivary diagnostics                                                                               Salivary proteins and nucleic acids   Less than 15 min             SDx (USA)
  Salivary diagnostics         IL-8 mRNA, IL-8 protein                                                                            Less than 15 min                      SDx (USA)                    

diagnostics-07-00039-t004_Table 4

###### 

Variety of emerging PoC technologies and their clinical utility and functions.

  Types of Emerging Technologies                         Biomarkers/Clinical Utility                                                                                                                                Technique Used                                                                                                                                                                                                        Function                                                                                                                       References
  ------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------
  Biosensors                                             Diabetes mellitus, (glucose biosensors), UTI, cardiac markers, acute leukaemias                                                                            Electrochemical                                                                                                                                                                                                       Drug delivery, cardio MEMS to monitor heart patients, hearing aids, insulin micropumps, endoscopic pills, retinal prosthesis   \[[@B79-diagnostics-07-00039]\]
  Fluorescent biosensors/FRET biosensor                  Drug discovery, arthritis, cancers, cardiovascular and neurodegenerative diseases, viral infections, chronic myeloid leukaemia                             Fluorescent probes are mounted through a receptor                                                                                                                                                                     They are able to probe gene expression, localisation of protein, signal transduction, transcription and cell cycle apoptosis   \[[@B77-diagnostics-07-00039]\]
  Biological Microelectromechanical Systems (BioMEMS)    Drug delivery, cardio MEMS, insulin micro pumps, endoscopic pills, retinal prosthesis                                                                      lab-on-a-chip systems/micro/nano-scale fabrication                                                                                                                                                                    Detection of, proteins, viruses, DNA and microorganisms                                                                        \[[@B80-diagnostics-07-00039],[@B81-diagnostics-07-00039]\]
  Microfluidics/paper based technology                   Stomach cancer biomarkers (*H. pylori*), detection of urine metabolites, blood glucose, pH value, liver function, infectious agents                        Optoelectronic and microfluidic system                                                                                                                                                                                DNA extraction, polymerase chain reaction (PCR) amplification                                                                  \[[@B83-diagnostics-07-00039]\]
  Electric field induced release and measurement EFIRM   IL-8 protein and IL-8 mRNA markers for oral cancer, non-squamous cell lung cancer (NSCLC) oncogenic mutation, EGFR mutation in no small cell lung cancer   Electrochemical                                                                                                                                                                                                       Liquid biopsy technique, selective hybridization                                                                               \[[@B57-diagnostics-07-00039],[@B84-diagnostics-07-00039]\]
  Smartphone based biosensors                            Blood samples of falciparum malaria infected and fluorescent images *M. tuberculosis*-positive sputum smears, self-monitoring of blood glucose, cancer     Metal-oxide semiconductor (CMOS)-based photo cameras, optical-based methods including absorbance, chemiluminescence, fluorescence, reflectance, surface plasmon resonance (SPR), bio- and electrochemilumines-cence   Detector system for reflectance, colorimetry and luminescence                                                                  \[[@B85-diagnostics-07-00039]\]
